Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Gross Margin (2020 - 2022)

Immuneering has reported Gross Margin over the past 3 years, most recently at 100.0% for Q4 2022.

  • Quarterly results put Gross Margin at 100.0% for Q4 2022, up 10877.0% from a year ago — trailing twelve months through Sep 2023 was 100.0% (up 7199.0% YoY), and the annual figure for FY2022 was 50.11%, up 555.0%.
  • Gross Margin for Q4 2022 was 100.0% at Immuneering, up from 49.6% in the prior quarter.
  • Over the last five years, Gross Margin for IMRX hit a ceiling of 100.0% in Q4 2022 and a floor of 8.77% in Q4 2021.
  • Median Gross Margin over the past 3 years was 50.55% (2022), compared with a mean of 47.78%.
  • Biggest five-year swings in Gross Margin: crashed -3762bps in 2021 and later surged 10877bps in 2022.
  • Immuneering's Gross Margin stood at 28.85% in 2020, then tumbled by -130bps to 8.77% in 2021, then soared by 1240bps to 100.0% in 2022.
  • The last three reported values for Gross Margin were 100.0% (Q4 2022), 49.6% (Q3 2022), and 49.23% (Q2 2022) per Business Quant data.